Levosimendan in the treatment of AHF: Lessons from surveys and clinical trials

European Journal of Heart Failure, Supplement

Volumn 7, Issue SUPPL. 2, 2008, Pages 228-233

  Mebazaa, Alexandre ^a   Delgado, Juan F ^b   Franco, Fatima ^c   Toller, Wolfgang ^d   Parissis, John ^e   Pini, Daniela ^f   Giannakoulas, George ^g   Gorjup, Vojka ^h   Karpati, Peter C J ^a   Follath, Ferenc ⁱ   Nieminen, Markku S ^j  

^a HÔPITAL LARIBOISIÈRE   (France)

^b HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^c CENTRO HOSPITALAR E UNIVERSITÁRIO DE COIMBRA   (Portugal)

^d MEDICAL UNIVERSITY OF GRAZ   (Austria)

^e UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^f HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^g ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^h UNIVERSITY MEDICAL CENTRE LJUBLJANA   (Slovenia)

ⁱ UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^j HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOBUTAMINE; DOPAMINE; FAS LIGAND; INOTROPIC AGENT; LEVOSIMENDAN; NITRATE; TROPONIN C; TUMOR NECROSIS FACTOR ALPHA; VASODILATOR AGENT;

ACUTE HEART FAILURE; ADVERSE OUTCOME; CLINICAL PRACTICE; CLINICAL TRIAL; CONTINUOUS INFUSION; DISEASE COURSE; DRUG BINDING; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; EUROPE; FRANCE; HEALTH SURVEY; HEART ATRIUM FIBRILLATION; HEART HEMODYNAMICS; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FAILURE; HEART OUTPUT; HEART VENTRICLE ARRHYTHMIA; HOSPITAL ADMISSION; HUMAN; HYPOKALEMIA; HYPOTENSION; KIDNEY FAILURE; LOADING DRUG DOSE; MORTALITY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROGNOSIS; QT INTERVAL; REGISTER; REVIEW; SIDE EFFECT; TORSADE DES POINTES; TREATMENT OUTCOME; TREATMENT RESPONSE; UNITED STATES;

EID: 77953856069     PISSN: 15674215     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1567-4215(08)60003-X     Document Type: Review

References (18)

1. Adams KF, Jr., Fonarow GC, Emerman CL, et al. Characteris-tics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE). Am Heart J 2005;149(2): 209-216.
2. Gheorghiade M, Abraham WT, Albert NM, et al. Systolic blood pressure at admission, clinical characteristics, and outcomes in patients hospitalized with acute heart failure. JAMA 2006;296(18): 2217-2226.
3. Cleland JG, Swedberg K, Follath F, et al. The EuroHeart Failure survey programme-a survey on the quality of care among patients with heart failure in Europe. Part 1: patient characteristics and diagnosis. Eur Heart J 2003;24(5):442-463. (Pubitemid 36286187)
4. Komajda M, Follath F, Swedberg K, et al. The EuroHeart Failure Survey programme-a survey on the quality of care among patients with heart failure in Europe. Part 2: treatment. Eur Heart J 2003; 24(5):464-474. (Pubitemid 36286188)
5. Nieminen MS, Brutsaert D, Dickstein K, et al. EuroHeart Failure Survey II (EHFS II): a survey on hospitalized acute heart failure patients: description of population. Eur Heart J 2006;27(22):2725-2736.
6. Tavazzi L, Maggioni AP, Lucci D, et al. Nationwide survey on acute heart failure in cardiology ward services in Italy. Eur Heart J 2006;27(10):1207-1215.
7. Zannad F, Mebazaa A, Juilliere Y, et al. Clinical profile, contem-porary management and one-year mortality in patients with severe acute heart failure syndromes: The EFICA study. Eur J Heart Fail 2006;8(7):697-705.
8. Siirila-Waris K, Lassus J, Melin J, et al. Characteristics, outcomes, and predictors of 1-year mortality in patients hospitalized for acute heart failure. Eur Heart J 2006;27(24):3011-3017.
9. Yancy CW, Lopatin M, Stevenson LW, De Marco T, Fonarow GC. Clinical presentation, management, and in-hospital outcomes of patients admitted with acute decompensated heart failure with pre-served systolic function: a report from the Acute Decompensated Heart Failure National Registry (ADHERE) Database. J Am Coll Cardiol 2006;47(1):76-84.
10. Moiseyev VS, Poder P, Andrejevs N, et al. Safety and efficacy of a novel calcium sensitizer, levosimendan, in patients with left ventricular failure due to an acute myocardial infarction. A ran-domized, placebo-controlled, double-blind study (RUSSLAN). Eur Heart J 2002;23(18):1422-1432.
11. Packer M. REVIVE II: Multicenter placebo-controlled trial of levosimendan on clinical status in acutely decompensated heart failure. Program and abstracts from the American Heart Associa-tion Scientific Sessions 2005 Dallas, Texas Late Breaking Clinical Trials II 2005.
12. Mebazaa A, Nieminen MS, Packer M, et al. Levosimendan vs dobutamine for patients with acute decompensated heart fail-ure: the SURVIVE Randomized Trial. JAMA 2007;297(17):1883-1891.
13. Follath F, Cleland JG, Just H, et al. Efficacy and safety of intra-venous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial. Lancet 2002;360(9328):196-202.
14. Logeart D, Thabut G, Jourdain P, et al. Predischarge B-type na-triuretic peptide assay for identifying patients at high risk of re-admission after decompensated heart failure. J Am Coll Cardiol 2004;43(4):635-641.
15. Giannakoulas G, Giannoglou G, Vassilikos V, et al. Clinical sig-nificance of acute neurohormonal response after levosimendan treatment. Am J Cardiol 2006;98(8):1123-1124.
16. Parissis JT, Adamopoulos S, Farmakis D, et al. Effects of se-rial levosimendan infusions on left ventricular performance and plasma biomarkers of myocardial injury and neurohormonal and immune activation in patients with advanced heart failure. Heart 2006;92(12):1768-1772.
17. Parissis JT, Andreadou I, Markantonis SL, et al. Effects of Lev-osimendan on circulating markers of oxidative and nitrosative stress in patients with advanced heart failure. Atherosclerosis 2007;195(2):e210-215.
18. Adamopoulos S, Parissis JT, Iliodromitis EK, et al. Effects of levosimendan versus dobutamine on inflammatory and apoptotic pathways in acutely decompensated chronic heart failure. Am J Cardiol 2006;98(1):102-106.